The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228).
Mohamed Bouchahda
No relevant relationships to disclose
Abdoulaye Karaboué
No relevant relationships to disclose
Marie-Christine Etienne-Grimaldi
No relevant relationships to disclose
Etienne Chatelut
No relevant relationships to disclose
Pasquale F. Innominato
No relevant relationships to disclose
Gilles Paintaud
No relevant relationships to disclose
Luana Ricca
No relevant relationships to disclose
Eric Vibert
No relevant relationships to disclose
Yves Ajavon
No relevant relationships to disclose
Sameh Awad
No relevant relationships to disclose
Denis Castaing
No relevant relationships to disclose
C. N. J. Focan
No relevant relationships to disclose
Gerard Milano
No relevant relationships to disclose
Jean Francois Morere
No relevant relationships to disclose
Rene Adam
No relevant relationships to disclose
Francis Levi
No relevant relationships to disclose